Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended September 30, 

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2025

    

2024

    

2025

    

2024

EmrosiTM

$

4,883

$

$

9,748

$

Qbrexza®

7,361

7,583

19,470

19,435

Accutane®

 

2,769

 

3,996

 

9,818

 

15,534

Foam franchise products (Amzeeq® & Zilxi®)

1,311

2,100

3,973

4,703

Other / legacy

701

950

2,164

2,842

Total product revenues

$

17,025

$

14,629

$

45,173

$

42,514

Schedule of other revenue

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

($ in thousands)

    

2025

    

2024

    

2025

    

2024

Cutia supply of Amzeeq

$

606

$

$

606

$

Total other revenues

$

606

$

$

606

$